|
TWI329105B
(en)
|
2002-02-01 |
2010-08-21 |
Rigel Pharmaceuticals Inc |
2,4-pyrimidinediamine compounds and their uses
|
|
WO2005012294A1
(en)
*
|
2003-07-30 |
2005-02-10 |
Rigel Pharmaceuticals, Inc. |
2,4-pyrimidinediamine compounds for use in the treatment or prevention of autoimmune diseases
|
|
WO2006045010A2
(en)
*
|
2004-10-20 |
2006-04-27 |
Resverlogix Corp. |
Stilbenes and chalcones for the prevention and treatment of cardiovascular diseases
|
|
US20060121040A1
(en)
*
|
2004-12-08 |
2006-06-08 |
Wisconsin Alumni Research Foundation |
Compositions and methods for treating neuroendocrine tumors
|
|
USRE46558E1
(en)
|
2005-04-28 |
2017-09-26 |
Paloma Pharmaceuticals, Inc. |
Compositions and methods to treat diseases characterized by cellular proliferation and angiogenesis
|
|
CA2610647C
(en)
*
|
2005-05-27 |
2015-02-03 |
Brian Smith |
Novel inhibitors of pyruvate kinase as therapeutic agents for cancer
|
|
US20070203161A1
(en)
|
2006-02-24 |
2007-08-30 |
Rigel Pharmaceuticals, Inc. |
Compositions and methods for inhibition of the jak pathway
|
|
BRPI0610876B8
(pt)
|
2005-06-08 |
2021-05-25 |
Rigel Pharmaceuticals Inc |
composto, formulação farmacêutica, e métodos de inibir uma atividade de uma jak cinase, e de inibir uma cascata de transdução de sinal em que jak3 cinase desempenha um papel
|
|
JP2008543855A
(ja)
|
2005-06-13 |
2008-12-04 |
ライジェル ファーマシューティカルズ， インコーポレイテッド |
変形性骨疾患を処置するための方法および組成物
|
|
ATE352714T1
(de)
*
|
2005-06-17 |
2007-02-15 |
Magneti Marelli Powertrain Spa |
Brennstoffeinspritzventil
|
|
US8410109B2
(en)
|
2005-07-29 |
2013-04-02 |
Resverlogix Corp. |
Pharmaceutical compositions for the prevention and treatment of complex diseases and their delivery by insertable medical devices
|
|
SG10202003901UA
(en)
|
2005-12-13 |
2020-05-28 |
Incyte Holdings Corp |
Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors
|
|
EP1976976A4
(en)
*
|
2005-12-23 |
2010-12-15 |
Univ Rochester |
TREATMENT OF NEURO-AIDS USING INHIBITORS OF GLYCODY SYNTHASE KINASE (GSK) -3
|
|
ES2622493T3
(es)
|
2006-02-24 |
2017-07-06 |
Rigel Pharmaceuticals, Inc. |
Composiciones y métodos para la inhibición de la ruta de JAK
|
|
JP2009528381A
(ja)
*
|
2006-02-28 |
2009-08-06 |
パロマ ファーマシューティカルズ，インク． |
細胞増殖および血管新生を特徴とする疾患を治療する組成物および方法
|
|
WO2007103308A2
(en)
|
2006-03-07 |
2007-09-13 |
Array Biopharma Inc. |
Heterobicyclic pyrazole compounds and methods of use
|
|
US8133867B2
(en)
|
2006-03-20 |
2012-03-13 |
Seikagaku Corporation |
Method for treating rheumatoid arthritis with an antibody that binds to a hepatocyte growth factor receptor
|
|
JP2009539878A
(ja)
*
|
2006-06-08 |
2009-11-19 |
アレイ バイオファーマ、インコーポレイテッド |
キノリン化合物および使用方法
|
|
WO2008006099A2
(en)
*
|
2006-07-07 |
2008-01-10 |
Myriad Genetics, Inc. |
Treatment of psychiatric disorders
|
|
PT2118074E
(pt)
*
|
2007-02-01 |
2014-03-20 |
Resverlogix Corp |
Compostos para a prevenção e tratamento de doenças cardiovasculares
|
|
KR20150036210A
(ko)
|
2007-06-13 |
2015-04-07 |
인사이트 코포레이션 |
야누스 키나제 억제제（Ｒ）―３―（４―（７Ｈ―피롤로［２，３－ｄ］피리미딘―4―일）―1Ｈ―피라졸―1―일）―３―사이클로펜틸프로판니트릴의 염
|
|
HUE030912T2
(en)
|
2008-02-15 |
2017-06-28 |
Rigel Pharmaceuticals Inc |
Pyrimidine-2-amine compounds and their use as inhibitors of yak kinases
|
|
EP2255830A1
(en)
|
2008-03-03 |
2010-12-01 |
Takeda Pharmaceutical Company Limited |
Concomitant drug
|
|
US20110092452A1
(en)
*
|
2008-03-05 |
2011-04-21 |
The Regents Of The University Of Michigan |
Compositions and methods for diagnosing and treating pancreatic cancer
|
|
US20110021618A1
(en)
*
|
2008-03-25 |
2011-01-27 |
Paloma Pharmaceuticals, Inc. |
Methods of treating fibrotic disorders
|
|
US8063058B2
(en)
|
2008-04-16 |
2011-11-22 |
Portola Pharmaceuticals, Inc. |
Inhibitors of syk and JAK protein kinases
|
|
US8138339B2
(en)
|
2008-04-16 |
2012-03-20 |
Portola Pharmaceuticals, Inc. |
Inhibitors of protein kinases
|
|
AU2009238590A1
(en)
|
2008-04-22 |
2009-10-29 |
Portola Pharmaceuticals, Inc. |
Inhibitors of protein kinases
|
|
SI2346837T1
(sl)
|
2008-06-26 |
2015-05-29 |
Resverlogix Corporation |
Postopki pripravljanja kinazolinonskih derivatov
|
|
WO2010011836A2
(en)
*
|
2008-07-25 |
2010-01-28 |
Emory University |
Treating various disorders with 7,8-dihydroxyflavone and derivatives thereof
|
|
CN102137939A
(zh)
*
|
2008-08-29 |
2011-07-27 |
霍夫曼-拉罗奇有限公司 |
不依赖vegf的肿瘤的诊断和治疗
|
|
US20120046242A1
(en)
*
|
2008-12-24 |
2012-02-23 |
Massachusetts Institute Of Technology |
Molecular activators of the wnt/beta-catenin pathway
|
|
US8952021B2
(en)
|
2009-01-08 |
2015-02-10 |
Resverlogix Corp. |
Compounds for the prevention and treatment of cardiovascular disease
|
|
SI2396307T1
(sl)
|
2009-02-11 |
2015-02-27 |
Merck Patent Gmbh |
Novi amino azaheterockliäśni karboksamidi
|
|
KR101913109B1
(ko)
|
2009-03-18 |
2018-10-31 |
리스버로직스 코퍼레이션 |
신규한 소염제
|
|
US9757368B2
(en)
|
2009-04-22 |
2017-09-12 |
Resverlogix Corp. |
Anti-inflammatory agents
|
|
SI2432472T1
(sl)
|
2009-05-22 |
2019-11-29 |
Incyte Holdings Corp |
3-(4-(7H-pirolo(2,3-d)pirimidin-4-il)-1H-pirazol-1-il)oktan- ali heptan-nitril kot inhibitorji JAK
|
|
AR076794A1
(es)
|
2009-05-22 |
2011-07-06 |
Incyte Corp |
Derivados de n-(hetero)aril-pirrolidina de pirazol-4-il-pirrolo [2,3-d]pirimidinas y pirrol-3-il-pirrolo [2,3-d ]pirimidinas como inhibidores de la quinasa janus y composiciones farmaceuticas que los contienen
|
|
JP5763636B2
(ja)
|
2009-08-07 |
2015-08-12 |
メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ |
新規なアザ複素環化合物
|
|
TW201113285A
(en)
|
2009-09-01 |
2011-04-16 |
Incyte Corp |
Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
|
|
EP2493871B1
(en)
*
|
2009-10-30 |
2014-09-03 |
Domain Therapeutics |
Novel oxime derivatives and their use as allosteric modulators of metabotropic glutamate receptors
|
|
EP3354652B1
(en)
|
2010-03-10 |
2020-05-06 |
Incyte Holdings Corporation |
Piperidin-4-yl azetidine derivatives as jak1 inhibitors
|
|
PE20130216A1
(es)
|
2010-05-21 |
2013-02-27 |
Incyte Corp |
Formulacion topica para un inhibidor de jak
|
|
EP2579870B1
(en)
|
2010-06-09 |
2018-02-14 |
Emory University |
Trkb agonists and methods of use
|
|
UA110113C2
(xx)
|
2010-07-29 |
2015-11-25 |
|
Біциклічні азагетероциклічні карбоксаміди
|
|
AU2011282684B2
(en)
|
2010-07-29 |
2015-05-21 |
Merck Patent Gmbh |
Cyclic amine azaheterocyclic carboxamides
|
|
EP2975027A1
(en)
|
2010-11-01 |
2016-01-20 |
Portola Pharmaceuticals, Inc. |
Nicotinamides as jak kinase modulators
|
|
US9198911B2
(en)
|
2010-11-02 |
2015-12-01 |
The Trustees Of Columbia University In The City Of New York |
Methods for treating hair loss disorders
|
|
US9034884B2
(en)
|
2010-11-19 |
2015-05-19 |
Incyte Corporation |
Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as JAK inhibitors
|
|
PE20140146A1
(es)
|
2010-11-19 |
2014-02-06 |
Incyte Corp |
Derivados de pirrolopiridina y pirrolopirimidina sustituidos con ciclobutilo como inhibidores de jak
|
|
LT2643313T
(lt)
|
2010-11-24 |
2016-10-25 |
Merck Patent Gmbh |
Chinazolino karboksamido azetidinai
|
|
US9381187B2
(en)
|
2011-02-16 |
2016-07-05 |
Paloma Pharmaceuticals, Inc. |
Radiation countermeasure agents
|
|
US9493436B2
(en)
|
2011-04-26 |
2016-11-15 |
Indiana University Research And Technology Corporation |
Tyrosine phosphatase inhibitors and uses thereof to modulate the activity of enzymes involved in the pathology of Mycobacterium tuberculosis
|
|
CN103797010B
(zh)
|
2011-06-20 |
2016-02-24 |
因塞特控股公司 |
作为jak抑制剂的氮杂环丁烷基苯基、吡啶基或吡嗪基甲酰胺衍生物
|
|
TW201313721A
(zh)
|
2011-08-18 |
2013-04-01 |
Incyte Corp |
作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物
|
|
UA111854C2
(uk)
|
2011-09-07 |
2016-06-24 |
Інсайт Холдінгс Корпорейшн |
Способи і проміжні сполуки для отримання інгібіторів jak
|
|
PT2755965T
(pt)
|
2011-09-12 |
2017-11-02 |
Merck Patent Gmbh |
Novas imidazol aminas como moduladores da atividade quinase
|
|
US9321760B2
(en)
|
2011-09-12 |
2016-04-26 |
Merck Patent Gmbh |
Aminopyrimidine derivatives for use as modulators of kinase activity
|
|
CA2851996C
(en)
|
2011-11-01 |
2020-01-07 |
Resverlogix Corp. |
Pharmaceutical compositions for substituted quinazolinones
|
|
MX363551B
(es)
|
2011-11-23 |
2019-03-27 |
Portola Pharmaceuticals Inc Star |
Compuestos derivados de pirazina como inhibidores de cinasa.
|
|
EA027968B1
(ru)
|
2011-12-22 |
2017-09-29 |
Мерк Патент Гмбх |
Гетероциклические карбоксамиды в качестве модуляторов активности киназ
|
|
JP6126131B2
(ja)
*
|
2012-01-10 |
2017-05-10 |
ニンバス アイリス， インコーポレイテッド |
Ｉｒａｋ阻害剤およびその使用
|
|
WO2013152252A1
(en)
|
2012-04-06 |
2013-10-10 |
OSI Pharmaceuticals, LLC |
Combination anti-cancer therapy
|
|
TW201406761A
(zh)
|
2012-05-18 |
2014-02-16 |
Incyte Corp |
做爲ｊａｋ抑制劑之哌啶基環丁基取代之吡咯并吡啶及吡咯并嘧啶衍生物
|
|
WO2014018741A1
(en)
|
2012-07-27 |
2014-01-30 |
Emory University |
Heterocyclic flavone derivatives, compositions, and methods related thereto
|
|
WO2014058921A2
(en)
|
2012-10-08 |
2014-04-17 |
Portola Pharmaceuticals, Inc. |
Substituted pyrimidinyl kinase inhibitors
|
|
PH12020551186B1
(en)
|
2012-11-15 |
2024-03-20 |
Incyte Holdings Corp |
Sustained-release dosage forms of ruxolitinib
|
|
EP2920154B1
(en)
|
2012-11-16 |
2017-10-11 |
Merck Patent GmbH |
Novel imidazol-piperidinyl derivatives as modulators of kinase activity
|
|
US9580443B2
(en)
|
2012-11-16 |
2017-02-28 |
Merck Patent Gmbh |
Heterocyclic derivatives as modulators of kinase activity
|
|
US9765039B2
(en)
|
2012-11-21 |
2017-09-19 |
Zenith Epigenetics Ltd. |
Biaryl derivatives as bromodomain inhibitors
|
|
US9073878B2
(en)
|
2012-11-21 |
2015-07-07 |
Zenith Epigenetics Corp. |
Cyclic amines as bromodomain inhibitors
|
|
NZ706418A
(en)
|
2012-11-29 |
2019-09-27 |
Merck Patent Gmbh |
Azaquinazoline carboxamide derivatives
|
|
JP2016507496A
(ja)
|
2012-12-21 |
2016-03-10 |
ゼニス・エピジェネティクス・コーポレイションＺｅｎｉｔｈ Ｅｐｉｇｅｎｅｔｉｃｓ Ｃｏｒｐ． |
ブロモドメイン阻害剤としての新規複素環式化合物
|
|
RS62867B1
(sr)
|
2013-03-06 |
2022-02-28 |
Incyte Holdings Corp |
Postupci i intermedijeri za dobijanje inhibitora jak
|
|
AR095202A1
(es)
|
2013-03-11 |
2015-09-30 |
Merck Patent Gmbh |
Heterociclos como moduladores de la actividad quinasa
|
|
SMT202000315T1
(it)
|
2013-08-07 |
2020-07-08 |
Incyte Corp |
Forme di dosaggio a rilascio prolungato per un inibitore di jak1
|
|
RU2016141385A
(ru)
|
2014-03-24 |
2018-04-28 |
Дженентек, Инк. |
Лечение рака антагонистами с-мет и их корреляция с экспрессией hgf
|
|
EP3125935B1
(en)
|
2014-04-03 |
2019-10-23 |
Merck Patent GmbH |
Combinations of cancer therapeutics
|
|
US9498467B2
(en)
|
2014-05-30 |
2016-11-22 |
Incyte Corporation |
Treatment of chronic neutrophilic leukemia (CNL) and atypical chronic myeloid leukemia (aCML) by inhibitors of JAK1
|
|
EP3186257B1
(en)
*
|
2014-08-27 |
2019-02-06 |
Prexton Therapeutics SA |
Novel chromone oxime derivative and its use as allosteric modulator of metabotropic glutamate receptors
|
|
US10111885B2
(en)
|
2015-03-13 |
2018-10-30 |
Resverlogix Corp. |
Compositions and therapeutic methods for the treatment of complement-associated diseases
|
|
PT3341380T
(pt)
*
|
2015-08-27 |
2019-12-19 |
Prexton Therapeutics Sa |
Derivado de oxima de cromona penetrante no cérebro para a terapêutica da discinesia induzida por levodopa
|
|
GB201516905D0
(en)
*
|
2015-09-24 |
2015-11-11 |
Stratified Medical Ltd |
Treatment of Neurodegenerative diseases
|
|
EP3260445A1
(en)
*
|
2016-06-24 |
2017-12-27 |
Universität Konstanz |
Compounds for use as an anti-bacterial or anti-fungal agent and as a zinc sensor
|
|
US10759865B2
(en)
|
2017-08-22 |
2020-09-01 |
Eyal Levit |
Treatment of diabetes mellitus
|
|
WO2019113487A1
(en)
|
2017-12-08 |
2019-06-13 |
Incyte Corporation |
Low dose combination therapy for treatment of myeloproliferative neoplasms
|
|
EP3502095A1
(en)
|
2017-12-22 |
2019-06-26 |
Universität Konstanz |
Compound for use against pathogenic neisseria and haemophilus species and moraxella catarrhalis
|
|
SG11202007164UA
(en)
|
2018-01-30 |
2020-08-28 |
Incyte Corp |
Processes for preparing (1 -(3-fluoro-2-(trifluoromethyl)isonicotinyl)piperidine-4-one)
|
|
SMT202400306T1
(it)
|
2018-03-30 |
2024-09-16 |
Incyte Corp |
Trattamento dell'idrosadenite suppurativa utilizzando inibitori di jak.
|
|
US11833155B2
(en)
|
2020-06-03 |
2023-12-05 |
Incyte Corporation |
Combination therapy for treatment of myeloproliferative neoplasms
|
|
WO2022101459A1
(en)
|
2020-11-16 |
2022-05-19 |
Merck Patent Gmbh |
Kinase inhibitor combinations for cancer treatment
|